Related Experiment Videos
Visual field defects in pediatric patients on vigabatrin monotherapy
Francisco J Ascaso1, María J Lopez, José A Mauri
1Department of Ophthalmology, University Clinic Hospital, Zaragoza, Spain. adileza@comz.org
Documenta Ophthalmologica. Advances in Ophthalmology
|December 10, 2003
Summary
Vigabatrin (GVG) can cause visual field defects (VFD) in children. This study found 20% of pediatric patients on GVG monotherapy experienced VFD, primarily nasal field loss.
Area of Science:
- Pediatric Neurology
- Ophthalmology
- Pharmacology
Background:
- Vigabatrin (GVG) is an established antiepileptic medication for partial seizures in children and adults.
- Adult studies increasingly report visual field defects (VFD) linked to GVG therapy.
- Limited data exists on VFD prevalence and characteristics in pediatric patients using GVG.
Purpose of the Study:
- To retrospectively review clinical data to determine the prevalence of VFD in pediatric patients on GVG monotherapy.
- To characterize the specific features of VFD observed in this pediatric cohort.
Main Methods:
- Retrospective review of 15 pediatric patients (ages 6-18) treated with GVG monotherapy.
- Visual field examination conducted using Humphrey Field Analyzer Program 30-2 static threshold automated perimetry.
- Data collected on patient demographics and visual field test results.
Main Results:
- Three out of fifteen pediatric patients (20%) demonstrated VFD.
- Observed VFD were bilateral, relatively symmetrical, and localized to the nasal field.
- A relative preservation of the temporal field within the central 30 degrees was noted.
Conclusions:
- Vigabatrin monotherapy is associated with a 20% prevalence of VFD in pediatric patients.
- The VFD pattern in children mirrors that seen in adults, characterized by nasal field loss.
- Routine visual field monitoring is crucial for pediatric patients undergoing GVG treatment.